Regarding CTLA4, its deficiency improved proliferation and anti-tumor efficacy in preclinical models of leukemia and myeloma, rescuing the function of T cells from patients with leukemia who previously failed CAR-T cell treatment (231). This evidence concerns the gene CTLA4 and leukemia.